Home World News EMA Recommends Extending Indications for Durvalumab World News EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 792 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 2020 Cancer Incidence and Mortality in EU-27 Countries July 24, 2020 How to Talk About Advanced Cancer Care Planning: An Expert Discussion November 20, 2023 Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 Load more HOT NEWS First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... Lessons from the green: How sports psychology helped a top golf... Five Questions with…Fred. First Global Estimates of Cervical Cancer Attributable to HIV
